This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It

Revolution Medicines (RVMD) has surged 125% in 2026, drawing a major bet from billionaire Stanley Druckenmiller's Duquesne Family Office, which purchased 316,000 shares worth $30.6 million in Q1. That position has since appreciated to $56.6 million as the pre-revenue biotech advances its flagship cancer drug.

The catalyst: Daraxonrasib, the company's targeted therapy designed to replace chemotherapy, received FDA Breakthrough Therapy designation and is now under accelerated review by the European Medicines Agency. The dual regulatory fast-track signals potential for earlier commercialization than standard development timelines.

Druckenmiller's nearly $31 million entry represents a conviction play on the clinical and regulatory trajectory. The position size and timing—ahead of potential EMA approval milestones—suggest his team sees asymmetric upside despite Revolution Medicines generating no revenue yet.

The stock's triple-digit gain reflects market anticipation around Daraxonrasib's regulatory path and commercial potential in oncology, a sector where breakthrough designations often compress approval timelines and de-risk binary outcomes.